KR880011142A - 피페라지닐-헤테로 시클릭 화합물 - Google Patents

피페라지닐-헤테로 시클릭 화합물 Download PDF

Info

Publication number
KR880011142A
KR880011142A KR1019880002163A KR880002163A KR880011142A KR 880011142 A KR880011142 A KR 880011142A KR 1019880002163 A KR1019880002163 A KR 1019880002163A KR 880002163 A KR880002163 A KR 880002163A KR 880011142 A KR880011142 A KR 880011142A
Authority
KR
South Korea
Prior art keywords
optionally substituted
fluoro
compound according
chloro
benzoisothiazolyl
Prior art date
Application number
KR1019880002163A
Other languages
English (en)
Other versions
KR900003492B1 (ko
Inventor
아담스 로우에 3세 존
Original Assignee
원본미기재
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22202301&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880011142(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 원본미기재, 화이자 인코포레이티드 filed Critical 원본미기재
Publication of KR880011142A publication Critical patent/KR880011142A/ko
Application granted granted Critical
Publication of KR900003492B1 publication Critical patent/KR900003492B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

내용 없음

Description

피페라지닐-헤테로 시클릭 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하기 일반식으로 표시되는 화합물 또는 그의 제약상 허용되는 산부가염.
    상기 식중, Ar은 플루오로, 클로로, 트리플루오로메틸, 메톡시, 시아노 또는 니트로에 의해 임의로 치환된 나프틸, 퀴놀릴, 6-히드록시-8-퀴놀릴, 이소퀴놀릴, 퀴나졸릴, 플루오로, 클로로, 트리플루오로메틸, 메톡시, 시아노 또는 니트로에 의해 각각 임의로 치환된 벤조이소티아졸릴 또는 그의 산화물 또는 이산화물, 벤조티아졸릴, 벤조트리아졸릴벤조티아디아졸릴, 벤조사족릴, 벤족사졸로닐, 인돌릴, 1 또는 2개의 플루오로에 의해 임의로 치환된 인다닐, 1-트리플루오르메틸페닐에 의해 임의로 치환된 3-인다졸릴, 또는 프탈라지닐이고, n은 1 또는 2이고, X 및 Y는 이들이 결합된 폐닐기와 함께 퀴놀릴, 2-히드록시퀴놀릴, 벤조티아졸릴, 2-아미노벤조티아졸릴, 벤조이소티아졸릴, 인다졸 릴, 2-히드록시인다졸릴, 인돌릴, 스피로[시클로펜탄-1,3′-인돌리닐], 1 내지 3개의 (C1-C3)알킬에 의해 임의로 치환되거나 또는 1개의 클로로, 플루오로 또는 페닐(이 페닐은 1게의 클로로 또는 플루오로에 의해 임의로 치환됨)에 의해 임의로 치환된 옥신돌릴, 벤족사졸릴, 2-아미노벤족사졸릴, 벤족사졸로닐, 2-아미노벤족사졸리닐, 벤조티아졸로닐, 벤조이미다졸로닐, 또는 벤조트리아졸릴을 형성한다.
  2. 제1항에 있어서, X 및 Y가 이들이 결합된 폐닐기와 함께 벤족사졸리닐 또는 옥신돌을 형성하는 것을 특징으로 하는 화합물.
  3. 제1항 또는 제2항에 있어서, Ar이 나프틸기이고, n이 1임을 특징으로 하는 화합물.
  4. 제1항 또는 제2항에 있어서, Ar이 벤조이소티아졸릴이고, n이 1임을 특징으로 하는 화합물.
  5. 제1항 또는 제4항에중 어느 하나의 항에 의한 화합물 및 제약상 허용되는 담체로 되는 제약 조성물.
  6. 정신질환을 치료하기 위한 제1항에 의한 화합물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880002163A 1987-03-02 1988-03-02 피페라지닐-헤테로시클릭 화합물 KR900003492B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8700423 1987-03-02
USPCT/US87/00423 1987-03-02

Publications (2)

Publication Number Publication Date
KR880011142A true KR880011142A (ko) 1988-10-26
KR900003492B1 KR900003492B1 (ko) 1990-05-21

Family

ID=22202301

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002163A KR900003492B1 (ko) 1987-03-02 1988-03-02 피페라지닐-헤테로시클릭 화합물

Country Status (31)

Country Link
EP (1) EP0281309B1 (ko)
JP (1) JPH0710837B2 (ko)
KR (1) KR900003492B1 (ko)
CN (1) CN1015057B (ko)
AR (1) AR244673A1 (ko)
AT (1) ATE70833T1 (ko)
AU (1) AU583762B2 (ko)
BA (1) BA98296A (ko)
CA (1) CA1300139C (ko)
CZ (1) CZ281257B6 (ko)
DD (1) DD272077A5 (ko)
DE (3) DE3867089D1 (ko)
DK (1) DK173065B1 (ko)
EG (1) EG18398A (ko)
ES (1) ES2040838T3 (ko)
FI (1) FI91868C (ko)
GR (1) GR3003459T3 (ko)
HU (1) HU207860B (ko)
IE (1) IE60849B1 (ko)
IL (1) IL85495A (ko)
LU (1) LU90944I2 (ko)
MX (1) MX173362B (ko)
MY (1) MY103352A (ko)
NO (2) NO170977C (ko)
NZ (1) NZ223694A (ko)
PH (1) PH24119A (ko)
PL (1) PL157897B1 (ko)
PT (1) PT86866B (ko)
SU (1) SU1644716A3 (ko)
YU (1) YU46639B (ko)
ZA (1) ZA881447B (ko)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130573A (ja) * 1983-12-15 1985-07-12 Otsuka Pharmaceut Co Ltd ベンゾチアゾ−ル誘導体
US4720297A (en) * 1985-09-27 1988-01-19 Sumitomo Chemical Company, Limited Benzothiazolones, and their production and use as herbicides
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
FR2631625B1 (fr) * 1988-05-17 1992-10-16 Synthelabo Derives de phenyl-6 piperazinylalkyl-3 1h,3h-pyrimidinedione-2,4, leur preparation et leur application en therapeutique
US5015740A (en) * 1988-08-05 1991-05-14 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
US4957916A (en) * 1988-08-05 1990-09-18 Janssen Pharmaceutica N.V. Antipsychotic 3-piperazinylbenzazole derivatives
WO1990006303A1 (en) * 1988-12-02 1990-06-14 Pfizer Inc. Arylpiperidine derivatives
WO1991000863A1 (en) * 1989-07-07 1991-01-24 Pfizer Inc. Heteroaryl piperazine antipsychotic agents
EP0429341A3 (en) * 1989-11-20 1991-11-13 Rhone-Poulenc Sante Heterocyclic derivatives, their preparation and pharmaceuticals containing them
FR2655042B1 (fr) * 1989-11-29 1994-01-21 Adir Cie Nouvelles benzothiazolinones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5166156A (en) * 1989-12-20 1992-11-24 Adir Et Compagnie Naphthyl piperazines useful as 5-HT1A receptor ligands
US5162321A (en) * 1989-12-20 1992-11-10 Adir Et Compagnie 1-naphthyl piperazines useful as 5-HT1A receptor ligands
US5166157A (en) * 1989-12-20 1992-11-24 Adir Et Compagnie Naphthyl piperazines useful as 5-HT1A receptor ligands
US5162324A (en) * 1989-12-20 1992-11-10 Adir Et Compagnie Naphyl piperazines useful as 5-HT1A receptor ligands
FR2671350A1 (fr) * 1991-01-08 1992-07-10 Adir Nouveaux derives de benzisoxazole et de benzisothiazole, leur procede de preparation, et les compositions pharmaceutiques les renfermant.
US5268381A (en) * 1990-09-26 1993-12-07 Adir Et Compagnie Aminoalkyl-benzothiazolinone and -benzoxazolinone compounds having a high 5-HT1A affinity
FR2667068B1 (fr) * 1990-09-26 1994-09-09 Adir Nouvelles amines alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5147881A (en) * 1990-11-14 1992-09-15 Pfizer Inc 4-(1,2-benzisoxazolyl)piperidine antipsychotic agents
US5643784A (en) * 1990-12-04 1997-07-01 H, Lundbeck A/S Indan derivatives
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
NZ243065A (en) 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
DK55192D0 (da) * 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
DK78692D0 (da) * 1992-06-12 1992-06-12 Lundbeck & Co As H Dimere piperidin- og piperazinderivater
US5312925A (en) * 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
DK148392D0 (da) * 1992-12-09 1992-12-09 Lundbeck & Co As H Heterocykliske forbindelser
CN1050604C (zh) * 1993-02-04 2000-03-22 明治制果株式会社 具有抗精神病作用的化合物
FR2702214B1 (fr) * 1993-03-05 1995-04-14 Adir Nouveaux composés (aryl(alkyl)carbonyl)-hétérocycliques, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent.
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
ES2083319B1 (es) * 1993-09-20 1997-01-16 Pfizer Monohidrato de clorhidrato de 5-(2-(4-(1,2-benzisotiazol-3-il)-1-piperazinil)-etil)-6-cloro-1,3-dihidro-2h-indol-2-ona.
FR2717807B1 (fr) * 1994-03-22 1996-04-19 Adir Nouvelles 6- [(4-arylalkyl-1-piperazino)alkyl] benzothiazolinones, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FI951296A (fi) * 1994-03-22 1995-09-23 Adir Uudet aminoalkyylibentsotiatsolinonit, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
JP3274579B2 (ja) * 1995-01-12 2002-04-15 住友製薬株式会社 脳血管障害に伴う精神症候治療剤
US6187774B1 (en) * 1996-03-04 2001-02-13 Yoshitomi Pharmaceutical Industries, Ltd. Fused heterocyclic compounds and pharmaceutical applications thereof
TR199802241T2 (ko) * 1996-05-07 1999-02-22 Pfizer Inc.
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
FR2755690B1 (fr) * 1996-11-08 1998-12-18 Adir Nouveaux derives aminomethyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6150366A (en) * 1998-06-15 2000-11-21 Pfizer Inc. Ziprasidone formulations
AR030357A1 (es) 2000-08-18 2003-08-20 Lundbeck & Co As H Derivados 4 -, 5 -, 6 - y 7-indol
US7504395B2 (en) 2001-07-20 2009-03-17 Psychogenics, Inc. Treatment for attention-deficit hyperactivity disorder
AU2003233228A1 (en) * 2002-05-03 2003-11-17 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Novel spiro ketone and carboxylic acid derivatives as specific inhibitors for (po3h2) ser/(po3h2)thr-pro-specific peptidyl-prolyl-cis/trans-isomerases
AU2003267801A1 (en) * 2002-10-28 2004-05-13 Warner-Lambert Company Llc Oxindole substituted piperazine derivatives
CA2525866A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Treatment of psychotic and depressive disorders
WO2004100956A1 (en) * 2003-05-16 2004-11-25 Pfizer Products Inc. Method for enhancing cognition using ziprasidone
BRPI0410419A (pt) * 2003-05-16 2006-05-30 Pfizer Prod Inc tratamento para a ansiedade com ziprasidona
HUP0400953A3 (en) * 2004-05-11 2008-02-28 Egis Gyogyszergyar Nyilvanosan Piperazine derivatives of alkyl-oxindoles, pharmaceutical compositions containing them, process for producing them and their use
EP1751106B1 (en) * 2004-05-11 2008-10-29 EGIS Gyógyszergyár Nyrt Piperazine derivatives of alkyl oxindoles
US7728136B2 (en) 2004-06-18 2010-06-01 Lupin Limited Method for the preparation of aryl piperazinyl-heterocyclic compounds
ES2250000B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Procedimiento para la preparacion de ziprasidona.
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
HUP0600868A3 (en) * 2006-11-24 2009-03-30 Richter Gedeon Nyrt 5-{2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl}-6-chloro-1,3-dihydro-2h-indol-2-one hydrogen bromide polimorphs and process for their preparation
JO2642B1 (en) 2006-12-08 2012-06-17 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
JO2849B1 (en) * 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
AU2008240729B2 (en) 2007-04-23 2012-08-23 Janssen Pharmaceutica N.V. Thia(dia)zoles as fast dissociating dopamine 2 receptor antagonists
JP5431305B2 (ja) 2007-04-23 2014-03-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 高速解離性ドパミン２受容体アンタゴニストとしての４−アルコキシピリダジン誘導体
CA2729313C (en) 2008-07-03 2016-08-30 Janssen Pharmaceutica Nv Substituted 6-(1-piperazinyl)-pyridazines as 5-ht6 receptor antagonists
DK2307374T3 (en) 2008-07-31 2017-05-01 Janssen Pharmaceutica Nv PIPERAZIN-1-YLTRIFLUORMETHYL-SUBSTITUTED PYRIDINES AS QUICK DISSOCATING DOPAMIN-2 RECEPTOR ANTAGONISTS
LT2445502T (lt) * 2009-06-25 2017-09-25 Alkermes Pharma Ireland Limited Heterocikliniai junginiai, skirti neurologinių ir fiziologinių susirgimų gydymui
PL391810A1 (pl) 2010-07-14 2012-01-16 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Nowe sole ziprasidonu oraz sposoby ich otrzymywania
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
MA41169A (fr) * 2014-12-17 2017-10-24 Acraf Composés antibactériens à large spectre d'activité
EP3761983A1 (en) 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179505A (en) * 1977-03-30 1979-12-18 Janssen Pharmaceutica N.V. 5-[4-(Diarylmethyl)-1-piperazinylalkyl]benzimidazole derivatives
FR2536749A1 (fr) * 1982-11-25 1984-06-01 Cerm Cent Europ Rech Mauvernay (amino-2 ethyl)-6 benzoxazolinones substituees, leur preparation et leurs applications en therapeutique
US4554284A (en) * 1984-09-12 1985-11-19 Smithkline Beckman Corporation 7-(2-Aminoethyl)-1,3-benzthia- or oxa-zol-2(3H)-ones
JPH0625181B2 (ja) * 1985-03-27 1994-04-06 住友製薬株式会社 新規なイミド誘導体
ZA864632B (en) * 1985-06-22 1988-02-24 Sandoz Ltd Thiazoles,their production and pharmaceutical compositions containing them
NL8601494A (nl) * 1985-06-22 1987-01-16 Sandoz Ag Thiazolen, hun bereiding en farmaceutische preparaten die ze bevatten.
MX174210B (es) * 1987-02-17 1994-04-28 Pfizer Procedimiento para la preparacion de compuestos arilpiperazinil-alquilenfenil-p-heterociclicos

Also Published As

Publication number Publication date
CN1015057B (zh) 1991-12-11
SU1644716A3 (ru) 1991-04-23
CA1300139C (en) 1992-05-05
DK108388D0 (da) 1988-03-01
AR244673A1 (es) 1993-11-30
JPH0710837B2 (ja) 1995-02-08
ATE70833T1 (de) 1992-01-15
DE10299021I1 (de) 2002-09-26
PH24119A (en) 1990-03-05
IE60849B1 (en) 1994-08-24
PT86866A (pt) 1988-03-01
FI91868B (fi) 1994-05-13
AU583762B2 (en) 1989-05-04
MY103352A (en) 1993-06-30
EG18398A (en) 1993-02-28
NO2002004I2 (no) 2007-02-12
AU1253788A (en) 1988-09-01
NZ223694A (en) 1990-02-26
JPS63301861A (ja) 1988-12-08
DE3867089D1 (de) 1992-02-06
NO880901L (no) 1988-09-05
NO880901D0 (no) 1988-03-01
YU46639B (sh) 1994-01-20
NO170977C (no) 1993-01-06
PL157897B1 (pl) 1992-07-31
EP0281309A1 (en) 1988-09-07
MX173362B (es) 1994-02-23
DK173065B1 (da) 1999-12-13
NO170977B (no) 1992-09-28
GR3003459T3 (en) 1993-02-17
CZ281257B6 (cs) 1996-07-17
EP0281309B1 (en) 1991-12-27
CN88101642A (zh) 1988-09-14
IE880574L (en) 1988-09-02
FI880941A0 (fi) 1988-03-01
PL270925A1 (en) 1988-12-08
ES2040838T3 (es) 1993-11-01
CZ131788A3 (en) 1996-05-15
DD272077A5 (de) 1989-09-27
DE10299021I2 (de) 2007-05-10
MX10621A (es) 1993-09-01
HU207860B (en) 1993-06-28
HUT50330A (en) 1990-01-29
DK108388A (da) 1988-09-03
BA98296A (bs) 2001-09-14
YU40688A (en) 1989-12-31
IL85495A0 (en) 1988-07-31
FI880941A (fi) 1988-09-03
IL85495A (en) 1993-05-13
PT86866B (pt) 1992-05-29
ZA881447B (en) 1989-10-25
LU90944I2 (fr) 2002-10-07
FI91868C (fi) 1994-08-25
KR900003492B1 (ko) 1990-05-21

Similar Documents

Publication Publication Date Title
KR880011142A (ko) 피페라지닐-헤테로 시클릭 화합물
ATE26705T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeuren und deren derivate, verfahren zu ihrer herstellung, und pharmazeutische praeparate, die diese verbindungen enthalten.
KR950704320A (ko) Crf 길항제로서의 피롤로피리미딘(pyrrolopyrimidines as crf antagonists)
IT8024369A0 (it) Preparazione contenente metilsolfonilmetano e procedimenti per l'impiego e la purificazione di essa.
CA2331870A1 (fr) Nouveaux composes cycliques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FI870219A (fi) Hypoglykemiska tiazolidindioner.
RU93005057A (ru) Фармацевтические соединения, производные тиенобензодиазепина, способ их получения, фармкомпозиция и их использование
ES2108129T3 (es) Nuevos derivados de pirazina, su preparacion y empleo.
SE8703169L (sv) 1-(4-aminofenyl)-4-metyl-7,8-metylendioxi-3,4-dihydro-5h-2,3-bensodiazepin, syraadditionssalter derav samt forfarande for framstellning av densamma
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
HUP0004780A2 (hu) Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében
ATE90339T1 (de) Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel.
KR880011158A (ko) 기관지확장제의 치환된 1,2,4- 트리아조로[1,5-a] 트리아진
KR910011807A (ko) 4-벤질-5-페닐-2,4-디히드로-3h-1,2,4-트리아졸-3-온 및 진경제로서의 그 의 용도
KR880004810A (ko) 소화성 궤양 치료제
KR870006035A (ko) 신규 항균제 1-티에닐-4-옥소퀴놀린-3-카복실산 화합물의 제법
KR890003755A (ko) 7- (2- 메틸- 4- 아미노피롤리디닐)나프티리딘 및 퀴놀린 화합물
DE3887102D1 (de) Substituierte Derivate von 20,21-Dinoreburnamenin, Verfahren zur Herstellung und so hergestellte Zwischenprodukte, ihre Verwendung als Arzneimittel und diese enthaltende pharmazeutische Zusammenstellungen.
ATE15189T1 (de) Guanidine, verfahren zur herstellung und pharmazeutische praeparate enthaltend solche verbindungen.
ATE90095T1 (de) Optisch aktive produkte von 20,21dinoreburnamenin-derivaten,verfahren zur herstellung, ihre verwendung als arzneimittel und diese enthaltende pharmazeutische zusammenstellungen.
KR920003970A (ko) 혈중 요산 함량의 강하 방법
BE1002099A3 (fr) Nouvelles quinazolinones tetracycliques, leur preparation et leur utilisation comme medicaments.
KR920008035A (ko) 타이로신 유도체 및 그 제조방법
KR910011258A (ko) 녹내장의 치료방법
PT71725B (pt) 2-(2-chlor-4-cyclopropyl-phenyl-imino)-imidazolidin dessen saureadditionssalze diese enthaltende arzneimittel und verfah- ren zur herstellung derselben

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
EXPY Expiration of term